ES2568909T3 - Novedosos compuestos antagonistas del receptor de la neuroquinina 1 - Google Patents
Novedosos compuestos antagonistas del receptor de la neuroquinina 1 Download PDFInfo
- Publication number
- ES2568909T3 ES2568909T3 ES13720801T ES13720801T ES2568909T3 ES 2568909 T3 ES2568909 T3 ES 2568909T3 ES 13720801 T ES13720801 T ES 13720801T ES 13720801 T ES13720801 T ES 13720801T ES 2568909 T3 ES2568909 T3 ES 2568909T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- nr8r9
- optionally substituted
- hydrogen
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de formula general A**Fórmula** en donde n es 1 o 2; R1 y R2 son independientemente hidrógeno, C1-4 alquilo, C1-4 haloalquilo, C1-4 alcoxi, CD3 o halógeno; R3 es hidrógeno, C(>=O)OR7 o C1-4 alquilo opcionalmente sustituido con hidroxi o NR8R9; R4 es hidrógeno u oxo; R5 y R6 son independientemente hidrógeno, hidroxi, NR8R9, C(>=O)R7, C(>=O)OR7, C(>=O)NR8R9, C1-4 alquilo, en donde dicho C1-4 alquilo es opcionalmente sustituido con hidroxi, NR8R9 o un anillo heterocíclico de 5 o 6 miembros en donde dicho anillo heterocíclico de 5 o 6 miembros es opcionalmente sustituido con C1-4 alquilo o C(>=O)R7; o R5 y R6, junto con el átomo de carbono al que están unidos, forman >=CH2 o un heterocicloalquilo de 5 o 6 miembros, en donde dicho heterocicloalquilo es opcionalmente sustituido con C1-4 alquilo; R7 es hidrógeno o C1-4 alquilo; R8 y R9 son independientemente hidrógeno o C1-4 alquilo, o R8 y R9, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico de 5 o 6 miembros o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601902P | 2012-02-22 | 2012-02-22 | |
| US201261601902P | 2012-02-22 | ||
| PCT/EP2013/053319 WO2013124286A1 (en) | 2012-02-22 | 2013-02-20 | Novel neurokinin 1 receptor antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2568909T3 true ES2568909T3 (es) | 2016-05-05 |
Family
ID=48325586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13720801T Active ES2568909T3 (es) | 2012-02-22 | 2013-02-20 | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9181259B2 (es) |
| EP (1) | EP2817312B1 (es) |
| JP (1) | JP6111274B2 (es) |
| KR (1) | KR20140122764A (es) |
| CN (1) | CN104245702B (es) |
| AU (1) | AU2013224181A1 (es) |
| CA (1) | CA2864440A1 (es) |
| DK (1) | DK2817312T3 (es) |
| ES (1) | ES2568909T3 (es) |
| HK (1) | HK1205104A1 (es) |
| MX (1) | MX2014010012A (es) |
| PL (1) | PL2817312T3 (es) |
| RU (1) | RU2631319C2 (es) |
| SG (1) | SG11201404880UA (es) |
| TW (1) | TW201339161A (es) |
| WO (1) | WO2013124286A1 (es) |
| ZA (1) | ZA201405959B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2817312T3 (pl) * | 2012-02-22 | 2016-08-31 | Leo Pharma As | Nowe związki będące antagonistami receptora neurokininy 1 |
| SG11201501867UA (en) | 2012-10-11 | 2015-04-29 | Nerre Therapeutics Ltd | Novel uses |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| WO2015024203A1 (en) * | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
| US10744185B2 (en) * | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
| JP2019519592A (ja) * | 2016-06-29 | 2019-07-11 | メンロ セラピューティクス インコーポレイテッド | 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| GB0108595D0 (en) | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| UA77515C2 (en) * | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
| CA2590039A1 (en) * | 2004-12-14 | 2006-06-22 | Merck & Co., Inc. | Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists |
| EP2129381A1 (en) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| WO2009002770A1 (en) | 2007-06-22 | 2008-12-31 | Merck & Co., Inc. | 6.5-pyrrolopiperidine tachykinin receptor antagonists |
| PL2817312T3 (pl) * | 2012-02-22 | 2016-08-31 | Leo Pharma As | Nowe związki będące antagonistami receptora neurokininy 1 |
-
2013
- 2013-02-20 PL PL13720801T patent/PL2817312T3/pl unknown
- 2013-02-20 CA CA2864440A patent/CA2864440A1/en not_active Abandoned
- 2013-02-20 EP EP13720801.3A patent/EP2817312B1/en not_active Not-in-force
- 2013-02-20 JP JP2014558082A patent/JP6111274B2/ja not_active Expired - Fee Related
- 2013-02-20 ES ES13720801T patent/ES2568909T3/es active Active
- 2013-02-20 KR KR1020147026352A patent/KR20140122764A/ko not_active Application Discontinuation
- 2013-02-20 DK DK13720801.3T patent/DK2817312T3/en active
- 2013-02-20 RU RU2014138032A patent/RU2631319C2/ru not_active IP Right Cessation
- 2013-02-20 CN CN201380021175.4A patent/CN104245702B/zh not_active Expired - Fee Related
- 2013-02-20 AU AU2013224181A patent/AU2013224181A1/en not_active Abandoned
- 2013-02-20 MX MX2014010012A patent/MX2014010012A/es unknown
- 2013-02-20 US US14/380,078 patent/US9181259B2/en not_active Expired - Fee Related
- 2013-02-20 WO PCT/EP2013/053319 patent/WO2013124286A1/en active Application Filing
- 2013-02-20 SG SG11201404880UA patent/SG11201404880UA/en unknown
- 2013-02-21 TW TW102106062A patent/TW201339161A/zh unknown
-
2014
- 2014-08-14 ZA ZA2014/05959A patent/ZA201405959B/en unknown
-
2015
- 2015-06-08 HK HK15105430.0A patent/HK1205104A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140122764A (ko) | 2014-10-20 |
| CN104245702B (zh) | 2016-09-14 |
| PL2817312T3 (pl) | 2016-08-31 |
| AU2013224181A1 (en) | 2014-10-02 |
| RU2014138032A (ru) | 2016-04-10 |
| EP2817312B1 (en) | 2016-02-17 |
| ZA201405959B (en) | 2016-08-31 |
| WO2013124286A1 (en) | 2013-08-29 |
| CN104245702A (zh) | 2014-12-24 |
| CA2864440A1 (en) | 2013-08-29 |
| EP2817312A1 (en) | 2014-12-31 |
| DK2817312T3 (en) | 2016-04-11 |
| US9181259B2 (en) | 2015-11-10 |
| SG11201404880UA (en) | 2014-09-26 |
| MX2014010012A (es) | 2014-09-12 |
| US20150018345A1 (en) | 2015-01-15 |
| HK1205104A1 (en) | 2015-12-11 |
| JP2015511240A (ja) | 2015-04-16 |
| TW201339161A (zh) | 2013-10-01 |
| RU2631319C2 (ru) | 2017-09-21 |
| JP6111274B2 (ja) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| ES2618003T3 (es) | Compuestos tricíclicos sustituidos como inhibidores de FGFR | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| PE20151977A1 (es) | Nuevos derivados de purina | |
| DOP2014000287A (es) | Compuestos de fenoxietil piperidina | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |